Research Article
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib
Table 1
Patient baseline characteristics.
| Variable | n = 40 |
| Age, years (mean ± SD) | 40 ± 11 | Sex, n (%) | Male | 24 (60) | Female | 16 (40) | Spleen size, cm (mean ± SD) | 8 ± 3 | Laboratory parameters, median (range) | Hemoglobin (g/dL) | 9.5 ± 2.6 | White cell count (/μL) | 111,585 (20,390–498,470) | Peripheral blood basophils (%) | 1 (0–8) | Eosinophils (%) | 1 (0–5) | Platelet count (x103/μL) | 294 (31–1,123) | Peripheral blood blasts (%) | 8 (2–20) | Sokal risk groups, n (%) | Low (<0.8) | 17 (42.5) | Intermediate (0.8–1.2) | 7 (17.5) | High (>1.2) | 16 (40.0) | Hasford risk groups, n (%) | Low (≤780) | 12 (30.0) | Intermediate (781–1,480) | 15 (37.5) | High (>1,480) | 13 (32.5) | EUTOS risk groups, n (%) | Low risk (≤87) | 38 (95.0) | High risk (>87) | 2 (5.0) |
|
|